Genetron Holdings Limited (NASDAQ:GTH) shares rose 6% during mid-day trading on Monday . The stock traded as high as $17.46 and last traded at $17.39. Approximately 245,012 shares were traded during mid-day trading, a decline of 61% from the average daily volume of 636,176 shares. The stock had previously closed at $16.40.
GTH has been the topic of several analyst reports. BidaskClub upgraded Genetron from a “strong sell” rating to a “sell” rating in a research note on Sunday, November 29th. Canaccord Genuity reiterated a “buy” rating and issued a $19.00 target price on shares of Genetron in a research note on Wednesday, September 30th.
The stock has a 50 day moving average price of $13.75 and a two-hundred day moving average price of $12.33.
Several hedge funds have recently modified their holdings of the company. Jennison Associates LLC increased its position in shares of Genetron by 20.5% during the third quarter. Jennison Associates LLC now owns 910,427 shares of the company’s stock worth $10,870,000 after purchasing an additional 155,060 shares in the last quarter. Platinum Investment Management Ltd. raised its position in Genetron by 68.8% in the 3rd quarter. Platinum Investment Management Ltd. now owns 375,359 shares of the company’s stock valued at $4,482,000 after purchasing an additional 153,045 shares in the last quarter. Yong Rong HK Asset Management Ltd raised its position in Genetron by 108.3% in the 3rd quarter. Yong Rong HK Asset Management Ltd now owns 250,000 shares of the company’s stock valued at $2,985,000 after purchasing an additional 130,000 shares in the last quarter. Indus Capital Partners LLC acquired a new stake in Genetron in the 3rd quarter valued at about $574,000. Finally, Euro Pacific Asset Management LLC acquired a new stake in Genetron in the 3rd quarter valued at about $468,000. Institutional investors and hedge funds own 21.07% of the company’s stock.
Genetron Company Profile (NASDAQ:GTH)
Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early liver cancer screening services through laboratory developed tests services, such as HCCscreen, a proprietary assay for the early screening of liver cancer.
Read More: Moving Average Convergence Divergence (MACD)
Receive News & Ratings for Genetron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genetron and related companies with MarketBeat.com's FREE daily email newsletter.